Highlights of Vitreoretina

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  17 (2024)
Volume  16 (2023)
Volume  15 (2022)
Volume  14 (2021)
Volume  13 (2020)
Volume  12 (2019)
Volume  11 (2018)
Volume  10 (2017)
Volume  9 (2016)
Volume  8 (2015)
Volume  7 (2014)
Volume  6 (2013)
Volume  5 (2012)
Volume  2 (2010)
Related articles

VOLUME 8 , ISSUE 4 ( December, 2015 ) > List of Articles

REVIEW ARTICLE

Evaluación y Manejo del Edema Macular Diabético

Juan Carlos Mesa-Gutiérrez, Jairo Hoyos-Chacón, Antonio Rouras-López, Isabel Cabiró-Badimón, Vicente Amías-Lamana, José Porta-Monnet

Citation Information : Mesa-Gutiérrez JC, Hoyos-Chacón J, Rouras-López A, Cabiró-Badimón I, Amías-Lamana V, Porta-Monnet J. Evaluación y Manejo del Edema Macular Diabético. 2015; 8 (4):2-12.

DOI: 10.5005/hov-10102-08401

Published Online: 26-12-2020

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract
PDF Share
  1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464-74.
  2. Early Treatment Diabetic Retinopathy Study Group. ETDRS Report n° 9. Early photocoagulation for diabetic retinopathy. Ophthalmology 1991; 98: 766-95.
  3. West K, Erdreich L, Stober J. A detailed study of risk factors for retinopathy and nefropathy in diabetic patients. Diabets 1980; 29: 501-8.
  4. Dharma S, D'Amico D. HLA antigens and the development of diabetic retinopathy. Int Ophthalmol Clin 1993; 33: 93-9.
  5. García-Campos J, Figueroa-Ortiz LC. Patogenia del edema macular diabético. El edema macular del diabético. Editorial Glosa 2009; 27-44.
  6. Mesa-Gutiérrez JC, Porta-Monnet J, Cabiró-Badimón I, Amías-Lamana V, Rouras-López A. Protocolos de tratamiento de la maculopatía diabética. Annals d'Oftalomologia 2010; 18 (2): 86-91.
  7. Chang-Sue Y, Ching-Yu C, Fenq-Lih L, Wen-Ming H, Jorn-Hon L. Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography. Acta Ophthalmol Scand 2001; 79: 266-70.
  8. Hee M, Puliafito C, Duker J. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998; 105: 360-70.
  9. Brown J, Solon S, Bresler S. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004; 122: 33-5.
  10. Kim B, Smith S, Kaiser P. Optical coherence tomography patterns of diabetic macular edema. Am J Ophthalmol 2006; 142: 405-12.
  11. Otani T, Kishi S, Maruyama S. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999; 127: 688-93.
  12. Kichi S, Demaria C, Shimizu K. Vitreous cortex remnants at the fovea after vitreous detachments. Int Ophthalmol 1986; 9: 253-60.
  13. Giovannini A, Amato G, Mariotti C, Rippa A. Diabetic maculopathy induced by vitreo-macular traction: evaluation by optical coherence tomography. Doc Ophthalmol 1999; 97: 361-6.
  14. Panozzo G, Parolini B, Gusson E, Mercanti A. Diabetic macular edema: an OCT-based classification. Semin Ophthalmol 2004; 19: 13-20.
  15. Kang S, Sa H, Cho H, Kim J. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124: 653-8.
  16. Yanyali A, Horozoglu F, Celik E, Ercaik Y, Nohutcu A. Pars plana vitrectomy and removal of the internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol 2006; 16: 573-81.
  17. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C. Long-term effect of intravitreal bevacizumab in patients with chronicdiffuse macular edema. Retina 2008; 28: 1053-60.
  18. Chung E, Roh M, Kwon W, Koh H. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macualr edema. Retina 2008; 28: 957-63.
  19. Lovestam-Adrian M, Larsson J. Vitrectomy seems to be beneficial for advanced diffuse diabetic macular edema not responding to laser treatment. Int Ophthalmol 2005; 26: 21-6.
  20. Bhadir M, Ertan A, Mertoglu O. Visual acuity comparison of vitrectomy with and without internal limiting membrane removal in the treatment of diabetic macular edema. Int Ophthalmol 2005; 26: 3-8.
  21. Stefaniotou M, Aspiotios M, Kalogeropoulos C, Christodoulou A, Psylla M, Ioachim E, Alamanos I, Psilas K. Vitrectomy results for diffuse diabetic macular edema with and without inner limiting membrane removal. Eur J Ophthalmol 2004; 14: 137-43.
  22. Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2004; 242: 630-7.
  23. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-49.
  24. David J, Browning CM, Powers F, Powers ME. Comparison of the magnitude and time course of macular thinning induced by different interventions for diabetic macular edema: implications for sequence of application. Ophthalmology 2006; 113: 1713-19.
  25. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695-702.
  26. Campochiaro P, Brown D, Pearson A, Ciulla T, Boyer D, Holz F, et al. Longterm Benedit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626-35.
  27. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin)in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-705.
  28. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275-8.
  29. Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (Avastin) injection. Arch Ophthalmol 2006; 124: 1365.
  30. Mason JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjuntive treatment of proliferative diabetic retinopathy. Am J Opthalmol 2006; 142: 685-8.
  31. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, et al. Vascular endotelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-9.
  32. Chun DW, Heier JS, Topping TM, Duker JS, Banker JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706-12.
  33. The Macugen Diabetic Retinopathy Study Group. A phase II randomized, double-masked, trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
  34. Thomas ER, Wang J, Ege E, Madsen R, Hainsworth DP. Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol 2006; 142: 860-1.
  35. Haritoglou C, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandonfer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
  36. Elman M, Bressler N, Qin H, Beck R, Ferris F, Friedman S, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferres laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-14.
  37. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang G, Massin P, Schlingemann R, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-25.
  38. Nguyen QD, Shah SM, Khwaja AA. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-51.
  39. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992; 99: 753-9.
  40. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000; 130: 178-86.
  41. Harbour JW, Smiddy WE, Flynn HW Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996; 121: 405-13.
  42. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaliod and the inner limiting membrane. Retina 2000; 20: 126-33.
  43. Avic R, Karderli B, Avic B, Simsek S, Baykara M, Kahveci Z, et al. Pars plana vitrec tomy and removal of the internal limiting membrane in the treatment of chronic macular oedema. Graefes Arch Clin Exp Ophthalmol 2004; 242: 845-52.
  44. Recchia FM, Ruby AJ, Recchia CA. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am J Ophthalmol 2005; 139: 447-54.
  45. Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol 2005; 139: 795-801.
  46. Tachi N, Ogino N. Vitrectomy for diffuse diabetic macular edema in cases of diabetic retinopathy. Am J Ophthalmol 1996; 122: 258-60.
  47. Otani T, Kishi S. A cotrolled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002; 134: 214-19.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.